StoxEmcure Pharmaceuticals vs Dr. Lal Path Labs: share price & financials comparison
NSE: EMCURE vs LALPATHLAB · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Emcure Pharmaceuticals vs Dr. Lal Path Labs at a glance
Emcure Pharmaceuticals (EMCURE) has a market capitalisation of ₹44,804 Cr, against ₹33,443 Cr for Dr. Lal Path Labs (LALPATHLAB). Over the past year Emcure Pharmaceuticals has returned +78.3%, compared with +26.4% for Dr. Lal Path Labs. On valuation, Emcure Pharmaceuticals trades at a lower P/E of 41.0 versus 57.3. Dr. Lal Path Labs earns a higher return on equity (21.3% vs 20.5%). Emcure Pharmaceuticals comes out ahead on size, valuation, growth, momentum and technicals. Dr. Lal Path Labs comes out ahead on profitability. Across the scored metrics below, Emcure Pharmaceuticals leads on 9 and Dr. Lal Path Labs on 4. On StoxGud's 10-point checklist, Emcure Pharmaceuticals scores 9/10 and Dr. Lal Path Labs scores 9/10.
| Metric | Emcure Pharmaceuticals | Dr. Lal Path Labs |
|---|---|---|
| Size | ||
| Market cap | ₹44,804 Cr | ₹33,443 Cr |
| Revenue (latest FY) | ₹9,204 Cr | ₹2,763 Cr |
| Net profit (latest FY) | ₹924 Cr | ₹505 Cr |
| Valuation | ||
| P/E | 41.0 | 57.3 |
| P/B | 8.38 | 12.19 |
| Dividend yield | 0.13% | 0.67% |
| Profitability | ||
| Return on equity | 20.5% | 21.3% |
| Net profit margin | 10.7% | 19.2% |
| Operating margin | 20.4% | 29.5% |
| Growth | ||
| Revenue growth (YoY) | +24.3% | +19.6% |
| Net profit growth (YoY) | +33.7% | +27.6% |
| Revenue CAGR (multi-year) | — | +11.8% |
| Financial health | ||
| Debt to equity | 0.27 | 0.00 |
| Momentum | ||
| 1-month return | +26.4% | +4.3% |
| 1-year return | +78.3% | +26.4% |
| 3-year CAGR | — | +15.0% |
| 5-year CAGR | — | +1.7% |
| 10-year CAGR | — | +13.7% |
| Distance from 52W high | +0.0% | -1.8% |
| Technicals | ||
| RSI (14) | 94 | 68 |
| Price vs 200-day avg | +34.8% | +19.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Emcure Pharmaceuticals | Dr. Lal Path Labs |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Emcure Pharmaceuticals or Dr. Lal Path Labs?
Emcure Pharmaceuticals has a market cap of ₹44,804 Cr and Dr. Lal Path Labs has a market cap of ₹33,443 Cr as of 13 Nov 2026.
Which has a lower P/E, Emcure Pharmaceuticals or Dr. Lal Path Labs?
Emcure Pharmaceuticals has the lower P/E: Emcure Pharmaceuticals trades at 41.0 and Dr. Lal Path Labs at 57.3.
Which gave better returns in the last year, Emcure Pharmaceuticals or Dr. Lal Path Labs?
Emcure Pharmaceuticals did better: Emcure Pharmaceuticals returned +78.3% and Dr. Lal Path Labs returned +26.4% over one year.
What is the difference between Emcure Pharmaceuticals and Dr. Lal Path Labs?
Both are NSE-listed companies in Healthcare. Emcure Pharmaceuticals is about 1.3 times the size of Dr. Lal Path Labs by market cap. In the latest financial year Emcure Pharmaceuticals reported revenue of ₹9,204 Cr and Dr. Lal Path Labs ₹2,763 Cr. Operating margin is 20.4% for Emcure Pharmaceuticals and 29.5% for Dr. Lal Path Labs. Debt to equity is 0.27 for Emcure Pharmaceuticals and 0.00 for Dr. Lal Path Labs.
Which is better, Emcure Pharmaceuticals or Dr. Lal Path Labs?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Emcure Pharmaceuticals leads on 9 and Dr. Lal Path Labs on 4. Emcure Pharmaceuticals is ahead on size, valuation, growth, momentum and technicals. Dr. Lal Path Labs is ahead on profitability. On StoxGud's rules-based checklist Emcure Pharmaceuticals scores 9/10 and Dr. Lal Path Labs scores 9/10. This is information, not advice: consult a SEBI-registered adviser before investing.